As a leading factory in the pharmaceutical industry, we are proud to offer a range of high-quality products for research use only. Our portfolio includes Semaglutide Rybelsus, Ozempic, NN9535, OG217SC, and NNC 0113-0217, all of which are meticulously formulated and rigorously tested to ensure optimal efficacy and safety. Semaglutide Rybelsus and Ozempic are both GLP-1 receptor agonists used to treat type 2 diabetes, while NN9535 and OG217SC are potent compounds with potential therapeutic applications in various disease areas. NNC 0113-0217, on the other hand, is an innovative therapeutic peptide that shows promise in treating conditions such as heart failure. Whether you are a researcher or a clinician, you can trust our products to meet your scientific needs and advance your work.